D. Dorey

发表

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

M. Murray, M. Ramgopal, J. Mrus, 2019, HIV research & clinical practice.

Migration-induced HIV and AIDS in rural Mozambique and Swaziland

I. Raimundo, J. Crush, D. Dorey, 2010 .

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes

W. Wilkison, R. Dobbins, A. Sykes, 2015, Diabetes, obesity & metabolism.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

S. Oka, S. Walmsley, C. Orkin, 2020, The New England journal of medicine.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

P. Cahn, M. Ramgopal, A. Pozniak, 2013, The Lancet.

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance

A. Zolopa, J. Demarest, M. S. St. Clair, 2018, AIDS research and human retroviruses.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

S. Walmsley, M. Murray, Jenny Huang, 2020, AIDS and Behavior.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

S. Oka, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Traitement VIH : Une étude internationale dans le prestigieux New England Journal of Medicine

C. Orkin, E. Overton, D. Margolis, 2020 .